BAP1 Loss by Immunohistochemistry Predicts Improved Survival to First-Line Platinum and Pemetrexed Chemotherapy for Patients With Pleural Mesothelioma: A validation study

Amber Louw, Vasiliki Panou, Weronika Maria Szejniuk, Christos Meristoudis, Siaw Ming Chai, Chris van Vliet, Y. C. Gary Lee, Ian M. Dick, Tina Firth, Louise Andersen Lynggaard, Azadeh Birbaneh Asghari, Mogens Vyberg, Johnni Hansen, Jenette Creaney*, Oluf Dimitri Røe

*Kontaktforfatter

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

OriginalsprogEngelsk
TidsskriftJournal of Thoracic Oncology
Vol/bind17
Udgave nummer7
Sider (fra-til)921-930
Antal sider10
ISSN1556-0864
DOI
StatusUdgivet - jul. 2022

Bibliografisk note

Copyright © 2022 International Association for the Study of Lung Cancer. All rights reserved.

Fingeraftryk

Dyk ned i forskningsemnerne om 'BAP1 Loss by Immunohistochemistry Predicts Improved Survival to First-Line Platinum and Pemetrexed Chemotherapy for Patients With Pleural Mesothelioma: A validation study'. Sammen danner de et unikt fingeraftryk.

Citationsformater